Long-Term Prognosis of Hyperferritinemia Induced by Intravenous Iron Therapy in Patients Undergoing Maintenance Hemodialysis: A 10-Year, Single-Center Study.
Journal
International journal of nephrology
ISSN: 2090-214X
Titre abrégé: Int J Nephrol
Pays: United States
ID NLM: 101546753
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
07
2020
revised:
30
11
2020
accepted:
05
12
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
1
1
2021
Statut:
epublish
Résumé
Optimal ferritin level in hemodialysis patients between Japan and other countries is controversial. Long-term side effects of iron supplementation in these patients remain unclear. We aimed to elucidate whether past hyperferritinemia in hemodialysis patients was associated with high risk of death and cerebrovascular and cardiovascular diseases (CCVDs). This small retrospective cohort study included approximately 44 patients unintentionally supplemented with excessive intravenous iron. A significantly higher risk of CCVDs was observed in patients with initial serum ferritin levels ≥1000 ng/mL than in the remaining patients. High ferritin levels slowly decreased to <300 ng/mL in a median of 24.2 (10.5-46.5) months without treatment. However, compared with the remaining patients, only patients whose ferritin levels did not decrease to <300 ng/mL steadily had a significantly higher risk of all-cause death (hazard ratio, 9.6). Long-term hyperferritinemia due to intravenous iron therapy is a risk factor for death in maintenance hemodialysis patients. For a prolonged better prognosis, intravenous iron should be carefully administered so as to avoid hyperferritinemia in patients with hemodialysis.
Identifiants
pubmed: 33381315
doi: 10.1155/2020/8864400
pmc: PMC7762662
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8864400Informations de copyright
Copyright © 2020 Sayako Maeda et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest regarding the publication of this paper.
Références
Eur J Haematol. 2012 Jul;89(1):87-93
pubmed: 22435497
Heliyon. 2019 Jul 12;5(7):e02045
pubmed: 31338466
Hemodial Int. 2017 Jun;21 Suppl 1:S93-S103
pubmed: 28370957
Sci Rep. 2018 Jan 12;8(1):658
pubmed: 29330517
Nephrol Dial Transplant. 2018 Dec 1;33(12):2234-2244
pubmed: 30010940
Ther Apher Dial. 2010 Jun;14(3):240-75
pubmed: 20609178
Clin Kidney J. 2017 Dec;10(Suppl 1):i9-i15
pubmed: 29225818
Clin Exp Nephrol. 2010 Aug;14(4):349-55
pubmed: 20467772
Int J Hematol. 2016 Oct;104(4):440-5
pubmed: 27329123
Kidney Int. 2014 Oct;86(4):845-54
pubmed: 24759150
Blood Purif. 2016;42(1):56-63
pubmed: 27093060
Clin Exp Nephrol. 2017 Aug;21(4):685-693
pubmed: 27503345
Cochrane Database Syst Rev. 2019 Feb 21;2:CD007857
pubmed: 30790278
N Engl J Med. 2019 Jan 31;380(5):447-458
pubmed: 30365356
Am J Nephrol. 2017;46(2):120-130
pubmed: 28704813
Ther Apher Dial. 2004 Dec;8(6):443-59
pubmed: 15663544
Ther Apher Dial. 2010 Dec;14(6):505-40
pubmed: 21118359
Am J Kidney Dis. 2016 Nov;68(5):677-690
pubmed: 27321965
Presse Med. 2017 Dec;46(12 Pt 2):e269-e271
pubmed: 29169711
Semin Dial. 2011 May-Jun;24(3):269-71
pubmed: 21682768